Results 131 to 140 of about 2,738 (166)

Low‐density Lipoprotein Apheresis: An Overview

Therapeutic Apheresis and Dialysis, 2003
Abstract:  Atherosclerosis with myocardial infarction, stroke, and peripheral cellular disease still maintains its position at the top of morbidity and mortality statistics in industrialized nations. Established risk factors widely accepted are smoking, arterial hypertension, diabetes mellitus, and central obesity.
Rolf, Bambauer, Ralf, Schiel, Reinhard, Latza   +2 more
openaire   +2 more sources

Indications for low-density lipoprotein apheresis

The American Journal of Cardiology, 1994
Low-density lipoprotein (LDL) apheresis offers an additional approach to lipid lowering in patients with severe hypercholesterolemia who fail to respond adequately to diet and drug therapy. Well-defined criteria for patient selection have yet to be established for LDL apheresis.
B R, Gordon, E, Stein, P, Jones, D R, Illingworth   +3 more
openaire   +2 more sources

Lipoprotein apheresis influences monocyte subpopulations

Atherosclerosis Supplements, 2017
Monocytes can be differentiated into subpopulations depending on their expression profile of CD14 and CD16. CD16-positive monocytes are associated with coronary artery disease. Up to now, no data exist about the effect of lipoprotein apheresis (LA) on the distribution of monocyte subpopulations.80 patients who underwent LA at the University Hospital ...
Jellinghaus, S, Reich, C, Schatz, U, Tselmin, S, Ibrahim, K, Pfluecke, C, Schauer, A, Bornstein, S R, Hohenstein, B, Strasser, R H, Julius, U, Poitz, D M   +11 more
openaire   +3 more sources

Vascular access in lipoprotein apheresis: a retrospective analysis from the UK’s largest lipoprotein apheresis centre

The Journal of Vascular Access, 2018
Introduction: Lipoprotein apheresis (LA) has proven to be an effective, safe and life-saving therapy. Vascular access is needed to facilitate this treatment but has recognised complications. Despite consistency in treatment indication and duration there are no guidelines in place. The aim of this study is to characterise vascular access practice at the
Daniel J, Doherty, Alison, Pottle, George, Malietzis, Nadey, Hakim, Mahmoud, Barbir, Jeremy S, Crane   +5 more
openaire   +2 more sources

Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?

Atherosclerosis Supplements, 2017
According to current European guidelines, lipid lowering therapy for progressive cardiovascular disease including cardiovascular events has to be focused on a target level for LDL-C. In contrast for Lp(a) a threshold has to be defined with respect to the method of measurement.
V J J, Schettler, J, Ringel, S, Jacob, U, Julius, R, Klingel, F, Heigl, E, Roeseler, P, Grützmacher   +7 more
openaire   +2 more sources

Role of Low-Density Lipoprotein Apheresis

The American Journal of Cardiology, 2005
Low-density lipoprotein (LDL) apheresis has been shown to reduce plasma levels of total cholesterol, LDL cholesterol, and lipoprotein(a). In addition to these lipoprotein changes, LDL apheresis induces atherosclerosis regression, improves myocardial perfusion and endothelial function, and may reduce cardiovascular event rates.
openaire   +2 more sources

Actual situation of lipoprotein apheresis in patients with elevated lipoprotein(a) levels

Atherosclerosis Supplements, 2019
An elevation of lipoprotein(a) (Lp(a)) is an internationally recognized atherogenic risk factor, documented in epidemiological studies, in studies with Mendelian randomization and in genome-wide association studies (GWAS). At present, no drug is available to effectively reduce its concentration.
Julius, Ulrich, Tselmin, Sergey, Schatz, Ulrike, Fischer, Sabine, Birkenfeld, Andreas L, Bornstein, Stefan R   +5 more
openaire   +2 more sources

Current Topics on Low-Density Lipoprotein Apheresis

Therapeutic Apheresis and Dialysis, 2001
The prognosis of patients suffering from severe hyperlipidemia, sometimes combined with elevated lipoprotein (a) (Lp[a]) levels, and coronary heart disease (CHD) refractory to diet and lipid-lowering drugs is poor. For such patients, regular treatment with low-density lipoprotein (LDL) apheresis is the therapeutic option.
R, Bambauer, R, Schiel, R, Latza
openaire   +2 more sources

Lipoprotein(a) Measurement in Lipoprotein Apheresis: Time to Change?

Journal of Clinical Apheresis
ABSTRACTThe question of standardizing the measurement of lipoprotein(a) [Lp(a)] has been discussed for many years, but the unavailability of automated methods insensitive to the structural heterogeneity of Lp(a) and the transition to a new unit of measurement have delayed this process. The aim of this study is to compare, in subjects undergoing regular
Carmen Corciulo, Beatrice Dal Pino, Francesco Sbrana, Federico Bigazzi   +3 more
openaire   +2 more sources

Development of Immunosorbents for apoB‐Containing Lipoproteins Apheresis

Artificial Organs, 1995
Abstract: Three types of sorbents were developed for the specific removal of atherogenic apoB‐containing low‐density lipoprotein (LDL) and lipoprotein LDL(a) (Lp[a])from human plasma. Two sorbents contained monospecific sheep polyclonal or mouse monoclonal antibodies against human apoprotein B‐100. The third one was intended for specific removal of Lp(
S N, Pokrovsky, A V, Sussekov, I Y, Adamova, O I, Afanasieva, G F, Benevolenskaya, G A, Konovalov, V V, Kukharchuk   +6 more
openaire   +2 more sources